p16INK4a and p14ARF Tumor Suppressor Genes Are Commonly Inactivated in Cutaneous Squamous Cell Carcinoma  by Brown, Victoria L. et al.
p16INK4a and p14ARF Tumor Suppressor Genes Are Commonly
Inactivated in Cutaneous Squamous Cell Carcinoma
Victoria L. Brown, Catherine A. Harwood, Tim Crook,w James G. Cronin, David P. Kelsell, and
Charlotte M. Proby
Centre for Cutaneous Research, St Bartholomew’s and the Royal London School of Medicine and Dentistry, University of London, London, UK; wLudwig
Institute for Cancer Research, Imperial College Faculty of Medicine, London, UK
The p16INK4a and p14ARF tumor suppressor genes (TSGs) are encoded within the CDKN2A locus on chromosome
9p21 and function as cell cycle regulatory proteins in the p53 and RB pathways. Inactivation of these genes by genetic
and epigenetic changes has been described in some human cancers, but their importance in cutaneous squamous cell
carcinoma (SCC) has not been established. Our detailed examination of 40 cutaneous SCC revealed loss of
heterozygosity of 9p21 markers in 32.5% of cases. Mutational analysis conﬁrmed ﬁve point mutations in four of 40
SCCs. These mutations changed the amino acid sequence of p16INK4a in four tumors and p14ARF in three tumors.
Promoter methylation of p16INK4a and p14ARF was detected in 13 of 36 (36%) and 16 of 38 (42%) cases, respectively.
Absent protein expression was conﬁrmed by immunohistochemistry in 13 of 16 (82%) of the tumors with biallelic
inactivating events. Overall, the frequency of 9p21 alterations was 76% and for both p16INK4a and p14ARF, promoter
methylation is the commonest mechanism of gene inactivation. Alterations at this locus were signiﬁcantly more
common in tumors from immunocompetent compared with immunosuppressed individuals. These data conﬁrm the
importance of inactivation of p16INK4a and p14ARF TSGs in the pathogenesis of cutaneous SCCs.
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Cutaneous squamous cell carcinoma (SCC) is the second
most common cancer in Caucasians (Johnson et al, 1992).
The incidence of the disease is rising rapidly in Europe,
North America, and Australia (Holme et al, 2000; Alam and
Ratner, 2001; Ramsay et al, 2002). Almost all cases of this
carcinoma arise on sun-exposed areas of skin, implicating
chronic exposure to ultraviolet radiation as the major
etiological factor (Grossman and Leffell, 1997). Organ trans-
plant recipients have a 100-fold increased risk of developing
SCC, implying that immunosuppression may significantly
alter individual susceptibility to the disease (Lindelof et al,
2000). In these patients cutaneous SCC has a more
aggressive clinical course, a greater tendency to metasta-
size and a higher mortality rate when compared with the
general population (Martinez et al, 2003). Cutaneous SCC
can also arise from within chronic wounds, scars, burns, or
ulcers (Alam and Ratner, 2001).
The molecular events associated with the initiation and
progression of cutaneous SCC remain poorly understood.
The cyclin-dependent kinase inhibitor 2A (CDKN2A) locus
on human chromosome 9p21 is the second most commonly
altered gene locus in human cancer after p53 (Liggett and
Sidransky, 1998).
CDKN2A uniquely encodes for two candidate tumor
suppressor genes (TSG): p16INK4a and p14ARF. They share
common exons 2 and 3 but have alternatively spliced first
exons (exon 1a for p16INK4a; exon 1b for p14ARF). These first
exons are under the control of distinct promoters and
uniquely create two proteins that have no sequence
homology at the amino acid level (Stone et al, 1995). Both
genes function as crucial cell cycle regulators. p16INK4a
binds to CDK4 and CDK6, which prevent pRB phosphor-
ylation and G1–S phase progression (Serrano et al, 1993).
By binding to MDM2, p14ARF prevents both MDM2-
mediated p53 degradation and MDM2-mediated Rb
inactivation, causing arrest of the G1 and G2 phases of
the cell cycle (Bates et al, 1998; Stott et al, 1998). Therefore
loss of function of either p16INK4a or p14ARF may lead to
unrestrained cell cycling and uncontrolled cell growth, a
common alteration in the carcinogenic process.
Inactivation of the two TSG at the CDKN2A locus can
occur by a variety of genetic mechanisms including
mutations and deletions (Liggett and Sidransky, 1998).
Due to the unique arrangement of the exons, a mutation in
exon 2 has the potential to alter the amino acid sequence of
either or both of the genes. In addition to genetic mecha-
nisms, hypermethylation of the CpG islands of certain gene
promoters, including p16INK4a and p14ARF, is a significant
means of transcriptional silencing in a variety of tumor types
(Esteller et al, 2001b). The importance of this epigenetic
mechanism of gene silencing in almost every stage of the
Abbreviations: Bp, base pairs; CDKN2A, cyclin-dependent kinase
inhibitor 2A; HPV, human papillomavirus; LOH, loss of hetero-
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initiation and progression of human cancer has only recently
begun to be fully appreciated (Jones and Baylin, 2002).
Of the two genes, p16INK4a has been more intensively
studied and has been proven conclusively to play an
important role in carcinogenesis, particularly head and neck
SCC and familial melanoma (Reed et al, 1996; Liggett and
Sidransky, 1998). The role of p14ARF inactivation in human
cancers is less well established, but is supported by studies
of transgenic mice carrying a disrupted exon 1b which are
cancer-prone at an early age (Kamijo et al, 1997). In
addition, both p14ARF mutations and methylation can have a
deleterious functional effect (Zhang and Xiong, 1999; Rizos
et al, 2001; Esteller et al, 2001a). In cutaneous SCC there
has been relatively little published concerning the inactiva-
tion of p16INK4a and p14ARF genes. Knockout mice experi-
ments suggest a possible role for p14ARF in the initiation of
cutaneous SCC development (Serrano et al, 1996; Kamijo
et al, 1997) and for p16INK4a in determining the differentiation
status of skin squamous tumors (Sharpless et al, 2001). In
primary cutaneous SCC, loss of heterozygosity (LOH) at the
9p21 locus and CDKN2A mutations have been reported but
with disparate results (Quinn et al, 1994a, b; Kubo et al, 1997;
Kushida et al, 1999; Soufir et al, 1999; Saridaki et al, 2003).
Only one study has addressed the important mechanism of
gene promoter hypermethylation in this tumor type, looking
at p16INK4a alone (Soufir et al, 1999) and no previous work
has examined p14ARF promoter methylation.
We have performed a comprehensive study of the
CDKN2A locus in cutaneous SCC to establish the impor-
tance of p16INK4a and p14ARF inactivation in the pathogen-
esis of this tumor. Using highly specific and sensitive
techniques, a variety of possible mechanisms for gene
silencing have been examined, including correlation of the
results with protein expression.
Results
LOH analysis A total of 13 out of the 40 tumors (32.5%)
exhibited allelic loss/LOH at one or more markers for 9p21.
Eleven samples showed loss at all informative markers. This
data is summarized in Table I and representative examples
are given in Fig 1. No samples showed microsatellite
instability at this locus.
Mutational analysis Five different point mutations were
found in four of 40 SCC (Table II and Fig 2). All mutations
were in exon 2 and consisted of four single C to T nucleotide
changes and one double substitution CC to TT. Since these
all occurred in dipyrimidine sites, they are consistent with a
UVB fingerprint type of mutation. Corresponding genomic
DNA did not show these mutations confirming tumor
specificity.
Sample 31T had two different independent point muta-
tions in exon 2. LOH analysis had previously shown loss of
one allele in this tumor specimen implying that both muta-
tions must have occurred in the same allele. This was
confirmed by subsequent sub-cloning (data not shown).
Sample 49T had a double CC to TT mutation, which
would alter the amino acid sequence in two codons of
p16INK4a but only one of p14ARF.
Table I. LOH results
Case no. D9S171 D9S1748 D9S974
1   –
3 –  –
5   
8  – 
11   
14   
17   
18  – 
19   
20   
21 – – 
24   –
25  – 
26   
27   –
28 –  
29 – – 
31   –
32 –  –
33 –  –
34   
35   
36   –
37   
38   –
39  – 
40   
41   
42   –
44 –  
45 –  –
46  – 
47   
48   –
49   –
50 –  
51   
52   
53   –
54   
N 31 33 22
LOH 9 10 7
% LOH  N 29 30 32
 , loss of heterozygosity (LOH);  , retention of heterozygosity;  ,
homozygous/not informative; –, no result/not done.
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Two other samples 45T and 48T (and their corresponding
genomic DNA) showed a G to A nucleotide polymorphism
that is seen in 4%–6% of the general population (Bertram
et al, 2002).
Methylation analysis Using MSP, evidence of methylation
was observed for the p16INK4a promoter in 13 of 36 (36%)
samples and for the p14ARF promoter in 16 of 38 (42%)
samples (Fig 3). When initial bisulfite modification of DNA
was successful, all samples produced a product with the
primers specific for unmethylated DNA. This is due to
amplification of the normal stromal tissue present in the
initial biopsy specimen. In addition, in those samples with
positive methylation, it is possible that the unmethylated
band could also represent the partial methylation status of
the tumor cells or genetic diversity of the tumor cell
population. Four samples were methylated for both the
p16INK4a and p14ARF promoters: 32T, 35T, 44T, and 53T.
Biallelic events Combining all the results from LOH
studies, mutation screening and methylation analysis,
biallelic changes (i.e. two of these three possible events)
were present in ten of 38 samples for p16INK4a and six of 39
samples for p14ARF (Table III).
Immunohistochemical results p16INK4a expression was
detected in 20 of 40 cutaneous SCC, of which 75% were
graded þ (Fig 4). Neither the amount nor the intensity of
staining correlated with tumor differentiation status. In 23 of
36 (64%) cases there was concordance between the
presence/absence of protein expression and genetic/
epigenetic results. In seven of ten (70%) of tumors with
biallelic genetic/epigenetic events, there was no protein
expression evident.
p14ARF expression was seen in 17 of 40 (42.5%) of the
samples; 14 of these being classified as þ . In 23 of 37
(62%) cases there was concordance between the pre-
sence/absence of protein expression and genetic/epige-
netic results. In all of the six tumors with biallelic genetic/
epigenetic results, there was no protein expression evident.
Comparison of immune status with mechanistic data
For p16INK4a, eight of ten (80%) immunocompetent patients
had genetic/epigenetic events compared with 12 of 28
(43%) immunosuppressed individuals (Table IV). Results
were similar for p14ARF with 9 of 10 (90%) vs 16 of 29 (55%)
respectively (p¼0.05 for both p16INK4a and p14ARF, Fisher’s
exact probability test).
Table V summarizes the data on immune status, p14ARF
and p16INK4a events (mutation, methylation, and immuno-
histochemical expression) and highlights those tumors in
which bilallelic events were identified.
Discussion
In this study we report the systematic analysis of the
CDKN2A locus in a well-characterized series of cutaneous
SCC. We demonstrate that alterations at the CDKN2A locus
are common in these cancers and we show inactivation of
the two TSG at this locus via both genetic and epigenetic
mechanisms.
Our results show that LOH at 9p21 is frequent in
cutaneous SCC. The frequency of 9p21 allelic loss
observed in this study (32.5%) is consistent with the largest
previous study by Quinn et al (1994b) who found LOH in
31% of samples. But in two smaller series of cancers,
Kushida et al (1999) and Soufir et al (1999) were unable to
detect LOH. These three studies all used fewer markers
at 9p21 in mostly non-microdissected tumor DNA, with a
non-quantitative method of assessing LOH. Saridaki et al
Figure 1
Loss of heterozygosity (LOH) analysis. Units on the y-axis represent
intensity of fluorescent signal; on the x-axis is allele length in base pairs.
The y-axis scaling differs between samples because quantities of PCR
products vary in intensity. Examples show retention of heterozygosity
(LOH index 0.64) for sample 14 at marker D9S171 and complete loss of
the upper allele (LOH) for sample 31Tcompared to matched blood, 31B
(arrows) at marker D9S1748. Note stutter bands are evident prior to the
allele (highest peak) signal.
Table II. Mutations found in CDKN2A exon 2 and the consequent changes in amino acid sequence for p16INK4a and p14ARF proteins
Sample p16INK4a codon change p16INK4a amino acid change p14ARF codon change p14ARF amino acid change
31T ccc ) ctc Pro81Leu acc ) act Thr142Thr
31T ttc ) ttt Phe 90 Phe cct ) tct Pro152Ser
41T ccc ) ctc Pro114Leu gcc ) gct Ala175Ala
49T gcc ) gct Ala57Ala ccg ) ttg Pro118Leu
cga ) tga Arg58STOP ccg ) ttg Pro118Leu
54T cga ) tga Arg80STOP ccg ) ctg Pro141Leu
All nucleotide changes C ! T substitutions except for 49T that had a tandem CC ! TT mutation.
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(2003) has recently shown a higher rate of LOH of 52% in a
smaller series, which combined Bowen’s disease (carcino-
ma in situ) and SCC. The samples in the present work were
all histologically confirmed invasive SCC. Furthermore,
microdissected DNA was tested and a quantitative method
was used to calculate LOH. As such, our results are likely to
be a more accurate estimate of the true prevalence of LOH
at this locus in cutaneous SCC.
Using DHPLC, point mutations were detected in only four
of 40 samples (10%). The sensitivity of our methodology is
validated by detection of the Ala148Thr polymorphism that
is found in 4%–6% of the general population (Bertram et al,
2002) and was detected in two of 40 of our samples (both
tumor and genomic DNA from samples 45 and 48). All the
mutations carried a UV signature (Brash et al, 1991), reflec-
ting the importance of UV in the etiology of these tumors,
which all arose on sun-exposed sites. This finding also
provides evidence of a role for mutagenesis of the p16INK4a
and p14ARF genes in the pathogenesis of UV-induced SCC.
Each of the mutations occurred in exon 2, the exon most
commonly mutated in other human cancers. For p16INK4a,
two of the mutations result in amino acid substitutions
(Pro81Leu and Pro114Leu), whereas the other two muta-
tions result in premature termination of the protein (Arg58-
STOP and Arg80STOP). Each of these mutations has been
previously described in other human cancer types (Pollock
et al, 1996; Kubo et al, 1997; Fargnoli et al, 1998; Soufir et al,
1999; Bazan et al, 2002).
The two non-truncating mutations, Pro81Leu and
Pro114Leu, which both occur in the key ankyrin repeat
domains, result in functional impairment of the p16INK4a
protein, (Koh et al, 1995; Ranade et al, 1995). Both of the
premature termination p16INK4a mutations result in expres-
sion of truncated proteins lacking CDK binding activity
(Parry and Peters, 1996). Three of the p16INK4a mutations
also affect p14ARF. Of these, one (Pro118Leu) has previously
been described in a cutaneous SCC (Soufir et al, 1999). The
Figure 2
Examples of mutations found in two cutaneous SCCs. Denaturing
high-performance liquid chromatography traces (left) and correspond-
ing sequencing results (right) for samples 31 (upper panel) and 54
(lower panel). Sequencing traces show heterozygous C ! T base
changes (arrowed) in exon 2 at nucleotide (nt) positions 242 and 270 for
31T; 238 for 54T.
Figure3
Representative examples of 10% acrylamide gels of methylation
specific PCR products. The presence of a visible band in ‘‘U’’ lanes
indicates unmethylated genes (normal stromal tissue); in ‘‘M’’ lanes
indicates methylated genes. (A) p16INK4a is methylated in sample 21. (B)
p14ARF is methylated in samples 3, 8, 27. Positive (Pos) controls were
universally methylated or unmethylated DNA for the M and U PCR,
respectively. H2O served as a negative (Neg) control for both reactions.
Controls were included in every run. L¼marker ladder.
Table III. Summary of monoallelic and biallelic molecular
abnormalities in cutaneous SCC
Molecular
abnormalities
No. of SCC
with p16INK4a
alterations
No. of SCC
with p14ARF
alterations
None 18 14
LOH alone 4 8
Mutation alone 1 0
Methylation alone 5 11
LOHþmutation 2 1
LOHþmethylation 7 3
Mutationþ
methylation
1 1
LOHþmutationþ
methylation
0 1
SCC, squamous cell carcinoma; LOH, loss of heterozygosity.
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effect of these mutations on the function of p14ARF awaits
formal characterization; however, other human cancer-
associated point mutations have been shown to functionally
impair p14ARF by diminishing its ability to activate and
stabilize p53 (Zhang and Xiong, 1999; Rizos et al, 2001).
As described above, the mutations in CDKN2A target
both p16INK4a and p14ARF in three cases, implying selective
pressure to abrogate the function of both proteins during
tumorigenesis in squamous epithelium. Unusually, 31T in
which there was unequivocal evidence of LOH, contained
two independent exon 2 missense mutations on the
retained allele. One of these affects the amino acid
sequence of p16INK4a, the other p14ARF. The presence of
distinct mutations targeting each gene in 31T, 49T, and 54T,
strongly argues that loss of function in both proteins is a key
event in carcinogenesis in cutaneous SCC.
In this study, we did not examine exon 3 (which
contributes coding sequence to only the four most
c-terminal amino acids of p16INK4a) nor did we analyze
homozygous deletions. Homozygous deletions, while rela-
tively common in carcinoma cell lines are rare in primary
carcinomas (e.g. primary gastric carcinomas, Lee et al,
1997). Similarly, biallelic deletion is very rare in primary
carcinomas of prostate and liver (Herman et al, 1995; Peng
et al, 2002).
Our results show that methylation of the normally
unmethylated promoter regions of both genes is the most
common mechanism of inactivation in cutaneous SCC.
p14ARF promoter methylation has never previously been
examined in cutaneous SCC and was the commonest
abnormality found in our series. In addition, this is the first
formal demonstration of p16INK4a promoter methylation in
cutaneous SCC. In a previous study using Southern
blotting, it was reported that the p16INK4a promoter was
not methylated in cutaneous SCC (Soufir et al, 1999). It is
well recognized that the sensitivity of this method is sub-
stantially lower than MSP for detection of methylation
(Herman et al, 1996). Moreover, our study analyzed 40
cases in contrast to the eight SCC analyzed by Soufir and
co-workers. These factors may well account for the differ-
ences between the two studies. Our results accord well with
studies using MSP in other squamous cancers (Reed et al,
1996; Gasco et al, 2002; Huang et al, 2002). Further analysis
of our results reveals that p16INK4a was hypermethylated in
the presence of an unmethylated p14ARF in nine of 13 (69%)
of the cases; p16INK4a was unmethylated with p14ARF
hypermethylation in 12 of 16 (75%) of tumors and four
(10%) cases demonstrated methylation of both gene pro-
moters. Thus, consistent with previous studies of colorectal
carcinomas, methylation of the p16INK4a and p14ARF
promoters are independent events (Esteller et al, 2000).
Figure 4
Immunohistochemistry slides showing pre-
dominant nuclear staining for p16INK4a anti-
body in tumor 44 and p14ARF antibody in
tumor 29. Absence of expression is noted for
p16INK4a in tumor 54 and p14ARF in tumor 31.
Both these tumors had biallelic inactivating
events detectable.
Table IV. Comparison of genetic events in immunosuppressed
versus immunocompetent patients
p16INK4a alterations p14ARF alterations
Present Absent Present Absent
Immunosuppressed 12 16 16 13
Immunocompetent 8 2 9 1
p¼ 0.048 p¼0.050
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TableV. Summary table of all results for both p16INK4a and p14ARF genes
Sample no. IC/IS LOHa
p16INK4a alterations p14ARF alterations
Biallelic eventsMutationb Methylation Expression Mutationb Methylation Expression
1 IS Ret nr þ  
3 IS Ret  þ þ þ
5 IS Ret    
8 IS Ret   þ 
11 IS Ret  þ þ 
14 IS Ret þ   
17 IS Ret  þ þ  þ
18 IS LOH  þ  
19 IS Ret nr  nr þ
20 IS LOH nr  nr 
21 IS LOH þ þ   c
24 IC LOH nr þ  þ
25 IS Ret  þ  þ
26 IS Ret    
27 IS Ret  þ þ 
28 IS Ret    þ
29 IS Ret  þ þ þ þ þ
31 IC LOH Y   Y   c, d
32 IC LOH þ  þ  c, d
33 IS Ret   þ 
34 IS Ret  þ þ 
35 IS LOH þ  þ  c, d
36 IC LOH   þ  d
37 IC Ret   þ þ
38 IS LOH þ    c
39 IS LOH þ   þ c
40 IC LOH þ þ  þ c
41 IC Ret Y þ þ N   c
42 IS Ret þ þ  
44 IS Ret þ þ þ þ þ þ
45 IS Ret  þ  þ þ
46 IS Ret  þ þ  þ
47 IS Ret    
48 IC Ret  þ þ þ
49 IC Ret Y   Y þ  d
50 IS Ret þ þ þ  þ
51 IC LOH þ   þ c
52 IS Ret    þ
53 IS Ret þ þ þ 
54 IS LOH Y   Y þ  c, d
IC, immunocompetent; IS, immunosuppressed; LOH, loss of heterozygosity; Ret, retention of heterozygosity; nr, no result.
aSee Table I for details.
bSee Table II for details.
cBiallelic events for p16INK4a.
dBiallelic events for p14ARF.
INACTIVATION OF p16INK4a AND p14ARF IN CUTANEOUS SCC 1289122 : 5 MAY 2004
Epigenetic changes may predate genetic events in the
natural history of some carcinomas. For example, p14ARF
hypermethylation is present in 32% of colorectal adenomas
(Esteller et al, 2000) and p16INK4a hypermethylation occurs
in pre-malignant, dysplastic oral squamous lesions (Gasco
et al, 2002). It would therefore be of interest to test the pre-
malignant forms of cutaneous SCC, namely Bowen’s
disease and actinic keratoses, and chronically UV-exposed
skin, for this epigenetic abnormality.
Inactivation of the p16INK4a gene was associated with
absent protein expression in almost all tumor cells in a study
of head and neck SCC (Reed et al, 1996) and non-small cell
lung cancer (Sanchez-Cespedes et al, 1999). Absent mRNA
was also found to correlate with lack of p16INK4a protein
expression in a study of mycosis fungoides (Peris et al,
1999). In our study concordance with genetic events was
only found in 64% and 62% of samples for p16INK4a and
p14ARF, respectively. The most likely explanation for this is
that methylation is not homogeneous in the SCC under
study, but, rather, is restricted to a sub-population of tumor
cells. This latter suggestion is supported by the immuno-
histochemical findings, which in most positive cases was
patchy and heterogeneous throughout the tumor areas. This
resembles the expression pattern seen in p16INK4a methy-
lated oral and cervical SCC (Nuovo et al, 1999; Huang et al,
2002).
Tumors with biallelic inactivating events would be
expected to lack functional protein. Immunohistochemistry
confirmed that this was indeed the case in 13 of 16 of the
studied cases (all six of the p14ARF cases and seven of ten
of the p16INK4a cases). In each of the three tumors that
retained some p16INK4a expression, one of the events was
methylation of the p16INK4a promoter. The likely explanation
for these observations is that methylation-dependent
silencing occurred only in specific parts of the tumor, and
that residual areas of unmethylated p16INK4a were present in
each case in which p16INK4a was expressed. Use of in situ
MSP has shown considerable heterogeneity in squamous
carcinomas methylation, consistent with this explanation
(Nuovo et al, 1999). Three tumors, 31T, 32T, and 54T, had
biallelic events in both genes and all had no expression of
either protein on immunohistochemistry.
For both p16INK4a and p14ARF significantly more tumors
from immunocompetent individuals had genetic/epigenetic
inactivating events compared with cutaneous SCC from
immunosuppressed individuals. These results, however, are
in keeping with a previous study which reported less allelic
loss at chromosome 9p in skin tumors from immunosup-
pressed compared with immunocompetent patients (Reh-
man et al, 1997). The explanation for these findings remain
elusive, but one could speculate that the significantly higher
prevalence of human papillomavirus found in immunosup-
pressed cutaneous SCC obviates the need for direct
genetic/epigenetic TSG alterations, similar to the mechan-
ism proven in anogenital carcinomas (Harwood and Proby,
2002).
In conclusion, this is the largest and most comprehensive
study of the CDKN2A locus in cutaneous SCC reported to
date. Overall, the total frequency of 9p21 alterations was
76%, with abnormalities of p16INK4a detected in 53% of
cases studied and p14ARF changes present in 64%.
Promoter methylation in cutaneous SCC has never pre-
viously been demonstrated at this locus, but was the
predominant mechanism of inactivation for both genes in
our series. Biallelic events were common. These findings
emphasize the importance of p16INK4a and p14ARF TSG in
the pathogenesis of cutaneous SCC.
Materials and Methods
Patient characteristics Forty cutaneous, invasive SCC were
obtained from 39 patients, following informed consent. These
comprised 30 samples from 29 iatrogenically immunosuppressed
patients and 10 samples from 10 immunocompetent patients.
Twenty-nine patients were male and 10 female. All specimens were
primary lesions and arose on sun-exposed areas of skin; namely
face, scalp, upper limbs, and upper trunk.
Specimen preparation A small portion of tumor tissue was snap
frozen immediately at operation and stored at 701C. The
remainder was formalin-fixed, processed routinely and embedded
in paraffin. The diagnosis was confirmed histologically by H&E
staining of all samples. Venous blood was obtained from all but one
patient.
DNA extraction Genomic DNA was extracted from the frozen
tissue and venous blood using the Nucleon Genomic DNA
Extraction Kit (Tepnel Life Sciences, Manchester, UK) according
to the supplied protocol.
Microdissection and DNA isolation For the allelic imbalance
studies tumor-enriched DNA was required. This was obtained by
microdissection of a majority tumor cell population from up to six 8
mm sections cut from the paraffin blocks from each case. The
tumor area on each slide was identified by reference to an adjacent
hematoxylin and eosin-stained slide. The tumor tissue was
obtained by scraping off unstained, waxed slides, with a single-
edged razor blade. The tissue was placed in an eppendorf
microfuge tube and dewaxed in 1 mL xylene on a rotating wheel
for 1 h. After all the xylene had been removed, 4 mL Proteinase K
solution (14 mg per mL; Roche Diagnostics Ltd., East Sussex, UK)
and 100 mL 10% Chelex (Bio-Rad Laboratories, Hercules, CA)
solution were added, and the mixture incubated in a rotating oven
at 561C for 24 h. The tubes were then boiled at 1001C for 8 min to
inactivate the Proteinase K. After centrifugation, 5 mL aliquots of
the supernatant were used in the subsequent allelotyping PCR.
The samples were stored at 41C until used. From the one patient
for whom venous blood was not obtained, normal skin was
microdissected and genomic DNA extracted as described above.
Allelotype/LOH analysis Microdissected tumor DNA and
matched genomic DNA from each patient was analyzed for allelic
loss using three highly polymorphic microsatellite (dinucleotide
repeat) markers, D9S171, D9S1748, and D9S974, which span the
CDKN2A locus at 9p21. These markers were chosen because of
their location with respect to the CDKN2A exons (Fig 5). In addition
they all have a high informativity rate (heterozygosity score) and
produce a PCR product of a small enough size for successful
amplification of DNA from paraffin-embedded samples. All primer
oligonucleotide sequences are available through The Genome
Database (http://www.gdb.org). For each primer pair, the 50 end of
the forward primer was synthesized with a fluorescent label (6FAM
or HEX) using amidite-labelling chemistry. Amplification was
carried out using a standard PCR protocol (PCR reagents including
Taq polymerase supplied by Bioline, London, UK) on a Hybaid
Cycler (Hybaid Ltd, Middlesex, UK) using a 601C annealing
temperature for D9S171 and 651C for D9S1748 and D9S974. The
PCR products produced for each sample were pooled in a 1:1 ratio
in the presence of Hi-Di formamide (Applied Biosystems Warring-
ton, UK) and a 500-ROX internal size standard (Applied Biosys-
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tems). Genotyping was performed on an ABI 3100 automated DNA
Analyzer (Applied Biosystems), which is capillary based and laser
activated to detect fluorescent PCR products. The resultant allele
profiles for each sample were analyzed using ABI Genescan 3.1
software (Applied Biosystems), which yields quantification of
results in terms of trace peak size and height.
Assessment of allele loss Different marker traces were distin-
guishable by size and fluorescent tag/color. Heterozygous indivi-
duals were identified i.e. those with two PCR products of different
size in normal DNA. The sizes of the two alleles were assigned to
the peaks of the greatest height; smaller peaks were interpreted as
stutter bands caused by slippage of the polymerase. LOH was
assessed for each blood/tumor pair by a quantitative method
calculating the LOH index (Okabe et al, 2000). The LOH index is
defined as the allele ratio in normal DNA divided by the allele ratio
in the corresponding tumor DNA. The allele ratio is the peak height
of the smaller length allele divided by the peak height of the larger
length allele. Allelic loss was defined by an LOH index of less than
0.5 or more than 2.0 i.e. at least a 50% signal change in tumor
allele profile compared to normal allele profile.
Mutational analysis by denaturing high-performance liquid
chromatography (DHPLC) and direct sequencing Exons 1a, 1b,
and 2 of CDKN2A were amplified for each sample using primers
that spanned the entire exon and intron–exon boundary. The PCR
products for exons 1b and 2 were split to provide two overlapping
PCR products for ease of subsequent analysis. The primer
sequences used were as follows (PCR product sizes in base pairs
(bp) in brackets): exon 1a forward: GAAGAAAGAGGA-GGGGCTG;
reverse: GCGCTACCTGATTCCAATTC (340 bp); exons 1b-1 for-
ward: TCAGGGAAGGCGGGTGCG; reverse: GCCGCGGGATGT-
GAACCA (245 bp); Exons 1b-2 forward: GCCGCGAGTGAGGGTTTT;
reverse: CACCGGCGGTTATCTCCTC (263 bp); Exon 2A forward:
AGCTTCC-TTTCCGTCATGC; reverse: GCAGCACCACCAGCGTG
(203 bp); Exon 2B forward: GACCCCGCCACTCTCACC; reverse:
GTGCTGGAAAATGAATGC-TCTG (310 bp). PCR amplification was
carried out using 50–100 ng of the frozen tissue genomic DNA in a
standard PCR protocol (PCR reagents including Taq polymerase
supplied by Bioline). Five percent dimethyl sulfoxide (BDH
Laboratories, Poole, UK) was added to the reaction mixture for
optimal PCR amplification of GC-rich regions. The annealing
temperature for exons 1b and 2-2 was 601C and for exon 1a and
2A was 551C. The PCR products obtained were heated to 941C
PCR for 5 min followed by cooling to 401C at a rate of 0.031C per s
to ensure heteroduplex formation. Mutational analysis was then
carried out using DHPLC with the Transgenomic WAVE System
(Transgenomic, UK). The optimum temperatures for the analysis of
each PCR fragment were calculated using the WAVE-Maker
software (Transgenomic). Mutations in samples showing DHPLC
traces that varied from the wild-type profile were identified by
sequencing an independent PCR product. These PCR products
were first purified using a PCR purification kit (QIAquick; Qiagen,
Crawley, UK), followed by direct sequencing using ABI Prism Big-
Dye terminator chemistry (Applied Biosystems) in accordance with
the manufacturer’s instructions. Each sample was sequenced in
both forward and reverse directions in independent PCR reactions
and the products were analyzed on an ABI 377 automated
sequencer. Sequence electropherograms were aligned using
Sequence Navigator software (Applied Biosystems).
Methylation analysis For methylation specific PCR (MSP), geno-
mic DNA was bisulfite modified using the reagents supplied in the
CpGenome Modification Kit (Intergen Company, Oxford, UK), acc-
ording to the manufacturer’s instructions. To analyze the methyla-
tion status of both the p16INK4a and the p14ARF gene promoter
regions, MSP was carried out with separate reaction mixtures
using unmethylated (U) and methylated primers (M). Control
samples were included in every run: positive controls were bisulfite
modified universally methylated or unmethylated DNA (Intergen) in
the M and U PCR, respectively. Negative controls substituted
distilled water for DNA in the PCR. A ‘‘hot-start’’ PCR was
employed using AmpliTaq Gold polymerase (Roche). For p16INK4a
MSP was carried out using the CpG WIZ Amplification Kit
(Intergen). For p14ARF MSP, primers were synthesized as previously
described (Esteller et al, 2000) and used in a 25 mL reaction mixture
composed of: 2.5 mL 10  GeneAmp PCR Buffer II, 2.0 mL MgCl2
solution 25 mM, 4.0 mL 5 mM dNTP mix, U or M primer 20 pmol,
1 U AmpliTaq Gold polymerase and 5 mL (50 ng) bisulfite modified
DNA. The annealing temperature for both the U and M reactions
was 601C. PCR products were resolved on 10% non-denaturing
acrylamide gels. The sizes of the PCR fragments for the p16INK4a U
and M forms are 154 and 145 bp, respectively, and for the p14ARF
U and M forms are 132 and 122 bp, respectively.
Immunohistochemical analysis Serial 4 mm sections of formalin-
fixed, paraffin-embedded biopsy samples were cut and one
stained with H&E to confirm the histological diagnosis. Further
sections were stained for both p16INK4a and p14ARF proteins using
commercially available primary antibodies: p16INK4a/MTS1 Ab-7
(16P07) mouse monoclonal antibody (NeoMarkers Inc., Fremont,
California) and p14 ARF (C-18) (sc-8613) goat polyclonal antibody
(Santa Cruz Biotechnology, Inc.) Sections were dewaxed in xylene
and rehydrated through graded alcohol. Endogenous peroxidase
activity was inhibited by incubating in 3% hydrogen peroxide in
methanol for 10 min. Antigen retrieval was performed by boiling in
10 mM citrate buffer pH 6.0, for 4 min in a microwave. After
blocking of non-specific binding by pre-incubation with donor
horse/rabbit serum for 30 min, the primary antibody at a
concentration of 1:100 was added for overnight incubation at
41C. For detection, biotinylated horse anti-mouse (for p16INK4a)
or biotinylated rabbit anti-goat (for p14ARF) sera (Vectastain ABC
Kit, Vector Laboratories, Burlingame, California) were applied as
secondary antibodies for 30 min at room temperature, followed
by incubation with the avidin–biotin complex chromogen (Vecta-
stain) for 20 min at room temperature. The reaction was developed
using DAB (3,30-diaminobenzidine) chromogen solution (Biogenex
Liquid DAB, Biogenex, California) and counterstained with hema-
toxylin. Appropriate positive and negative control slides were
included in every run.
Interpretation of immunostaining Slides were assessed by two
independent observers (VB and CP). CP had no prior knowledge of
the clinical details or molecular studies. p16INK4a and p14ARF are
both nuclear proteins and only nuclear reactivity was considered
positive for protein expression. Internal positive controls included
infiltrating inflammatory cells and basal keratinocytes for p16INK4a
and appendageal structures, such as hair follicles and glandular
structures; for p14ARF. Staining was graded as negative (), less
than 5% of tumor nuclei positive or cytoplasmic staining only (  ),
less than 25% of tumor cells positive (þ ), 25%–50% of tumor cells
positive (þ þ ) or more than 50% of tumor cells positive (þ þ þ ).
Ethical approval This study was approved by the East London
and City Health Authority Research Ethics Committee.
Figure 5
Location of microsatellite markers used in allelotyping, relative to
CDKN2A exons.
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